Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Return on Sales (2019 - 2024)

Benitec Biopharma's Return on Sales history spans 6 years, with the latest figure at 3073.71% for Q1 2024.

  • For Q1 2024, Return on Sales fell 299320.0% year-over-year to 3073.71%; the TTM value through Mar 2024 reached 3073.71%, down 278983.0%, while the annual FY2023 figure was 254.85%, 984.0% down from the prior year.
  • Return on Sales for Q1 2024 was 3073.71% at Benitec Biopharma, down from 356.05% in the prior quarter.
  • Across five years, Return on Sales topped out at 70.32% in Q2 2020 and bottomed at 3933.75% in Q3 2021.
  • The 5-year median for Return on Sales is 272.07% (2023), against an average of 1091.7%.
  • The largest annual shift saw Return on Sales plummeted -388482bps in 2021 before it skyrocketed 372273bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 3261.0% in 2020, then soared by 94bps to 193.84% in 2021, then plummeted by -107bps to 401.36% in 2022, then increased by 11bps to 356.05% in 2023, then crashed by -763bps to 3073.71% in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Return on Sales are 3073.71% (Q1 2024), 356.05% (Q4 2023), and 272.07% (Q3 2023).